4.1 Article

Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial

Journal

Publisher

WILEY
DOI: 10.1002/hup.2412

Keywords

saffron; memantine; Alzheimer's disease; Crocus sativus L.; glutamate

Funding

  1. Iran National Science Foundation

Ask authors/readers for more resources

Objectives Limited pharmacological options are available for the management of Alzheimer's disease (AD) in severe stages. Cognitive-enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to severe AD. Methods In this randomized double-blind parallel-group study, 68 patients with moderate to severe AD (Mini-Mental State Examination score of 8-14) received memantine (20 mg/day) or saffron extract (30 mg/day) capsules for 12 months. Participants were evaluated every month by Severe Cognitive Impairment Rating Scale (SCIRS) and Functional Assessment Staging (FAST) in addition to recording the probable adverse events. Results Both treatment groups showed similar outcomes as demonstrated by insignificant effect for time x treatment interaction on SCIRS scores [F(2.95, 194.78) = 2.25, p = 0.08]. There was no significant difference between the two groups in the scores changes from baseline to the endpoint on SCIRS (p = 0.38) and FAST (p = 0.87). The frequency of adverse events was not significantly different between the two groups as well. Conclusions In addition to its favorable safety profile, 1-year administration of saffron extract capsules showed to be comparable with memantine in reducing cognitive decline in patients with moderate to severe AD. Confirmatory studies with larger sample sizes and longer follow-up periods are warranted. Copyright (C) 2014 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Substance Abuse

Substance of choice, impact of heroin or opium on treatment retention in a multicentre randomised controlled trial in Iran

Michael Jae Song, Jean Nicolas Westenberg, Kiana Kianpoor, Mohammadali Nikoo, Alireza Kazemi, Christian Schuetz, Kerry Jang, Ali Gholami, Shahin Akhondzadeh, Michael Krausz

Summary: In the Middle East and Asia, the use of illicit opioids, ranging from heroin to opium, varies greatly. However, the impact of the primary opioid of choice on opioid agonist treatment retention has not been thoroughly examined. This study investigated the relationship between primary opioid of choice (heroin or opium) and retention in opium tincture and methadone treatment. The results suggest that positive factors, such as employment, housing, and family support, may explain the higher retention in treatment among those who primarily use opium.

DRUG AND ALCOHOL REVIEW (2022)

Article Pharmacology & Pharmacy

Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial

Mahsa Motamed, Hanieh Karimi, Hossein Sanjari Moghaddam, Sina Taherzadeh Boroujeni, Zahra Sanatian, Alireza Hasanzadeh, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh

Summary: This study aimed to investigate the efficacy and safety of adalimumab therapy in patients with chronic schizophrenia. The results showed that adalimumab adjunctive therapy was effective in improving negative and general psychopathology symptoms of schizophrenia, with no side effects. However, it did not significantly improve positive symptoms. There were no significant differences in inflammatory biomarker levels between the adalimumab and placebo groups.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2022)

Article Substance Abuse

Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial

Mohammadali Nikoo, Kiana Kianpoor, Nooshin Nikoo, Sanam Javidanbardan, Alireza Kazemi, Fiona Choi, Marc Vogel, Ali Gholami, Saeed Tavakoli, James S. H. Wong, Ehsan Moazen-Zadeh, Reza Givaki, Majid Jazani, Fatemeh Mohammadian, Nader Markazi Moghaddam, Christian Schuetz, Kerry Jang, Shahin Akhondzadeh, Michael Krausz

Summary: This study aimed to compare the effectiveness of opium tincture (OT) and methadone in retaining participants in opioid agonist treatment (OAT). The results showed that OT retained 60% of participants to the end of the 85-day follow-up period and was superior to methadone in reducing self-reported opioid use outside of treatment. However, the study did not find sufficient evidence to conclude the non-inferiority of OT compared to methadone.

ADDICTION (2023)

Article Pharmacology & Pharmacy

Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial

Parnia Ebrahimi, Homa Seyedmirzaei, Kamyar Moradi, Sayna Bagheri, Mahdi Moeini, Mohammad-Reza Mohammadi, Shahin Akhondzadeh

Summary: This study aimed to evaluate the therapeutic effects of cilostazol on aberrant behaviors in children with autism spectrum disorder (ASD) and its safety profile. A double-blind, randomized clinical trial was conducted with 66 confirmed ASD children. The results showed that cilostazol had beneficial effects on hyperactivity in children with ASD and higher levels of hyperactivity, with no significant adverse effects observed.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

Initial Pharmacological Characterization of a Major Hydroxy Metabolite of PF-5190457: Inverse Agonist Activity of PF-6870961 at the Ghrelin Receptor((SIC))

Sara L. Deschaine, Morten A. Hedegaard, Claire L. Pince, Mehdi Farokhnia, Jacob E. Moose, Ingrid A. Stock, Sravani Adusumalli, Fatemeh Akhlaghi, James L. Hougland, Agnieszka Sulima, Kenner C. Rice, George F. Koob, Leandro F. Vendruscolo, Birgitte Holst, Lorenzo Leggio

Summary: The metabolite PF-6870961 of PF-5190457 has been identified as a potential treatment for alcohol use disorder. It shows binding affinity and inverse agonist activity at GHSR1a, and can suppress food intake in rats through GHSR receptor-mediated pathways.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Letter Clinical Neurology

Response to [Palmitoylethanolamide: one molecule, different formulations]

Hossein Sanjari Moghaddam, Shahin Akhondzadeh

PSYCHIATRY AND CLINICAL NEUROSCIENCES (2023)

Article Biochemistry & Molecular Biology

Investigating the relationship between early life adversity, inflammation and alcohol use

Jillian T. Battista, Daria Piacentino, Melanie L. Schwandt, Mary R. Lee, Monica L. Faulkner, Mehdi Farokhnia, Lorenzo Leggio

Summary: Early life adversity (ELA) has lasting effects on adult mental and physical health, including higher risk of psychiatric conditions such as depression, anxiety, and alcohol misuse. Inflammation, assessed through hsCRP, may mediate the relationship between ELA and alcohol use. Study findings indicate that early life stress and alcohol consumption are associated with increased hsCRP levels, suggesting that elevated inflammation may contribute to unhealthy alcohol use in adulthood.

ADDICTION BIOLOGY (2023)

Article Substance Abuse

A human laboratory study on the link between alcohol administration and circulating fibroblast growth factor 21 (FGF21) in individuals with alcohol use disorder

Mehdi Farokhnia, Tammy Wang, Tony Jourdan, Grzegorz Godlewski, Lisa A. Farinelli, George Kunos, Lorenzo Leggio

Summary: Growing evidence suggests that the interaction between the central nervous system and the periphery, particularly through fibroblast growth factor 21 (FGF21), plays a crucial role in the development of neuropsychiatric conditions and addictive disorders. This study examined the relationship between alcohol use disorder (AUD) and FGF21 levels in non-treatment seeking individuals using both outpatient and laboratory settings. The findings showed that while FGF21 levels remained stable during the outpatient phase, there was a significant increase in serum FGF21 concentrations following alcohol self-administration in a controlled laboratory experiment. These results highlight the potential of targeting the FGF21 system as a pharmacotherapy for AUD.

DRUG AND ALCOHOL DEPENDENCE (2023)

Article Clinical Neurology

L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial

Mehran Nematizadeh, Hossein Ghorbanzadeh, Hossein Sanjari Moghaddam, Mohammadreza Shalbafan, Mahsa Boroon, Amir-Abbas Keshavarz-Akhlaghi, Shahin Akhondzadeh

Summary: The main aim of this study was to investigate the additional effects of L-theanine on OCD symptoms in combination with fluvoxamine. The results suggest that L-theanine can be a relatively safe and effective adjuvant therapy for moderate to severe OCD.

PSYCHIATRY AND CLINICAL NEUROSCIENCES (2023)

Article Medicine, Research & Experimental

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission

Vicky Chuong, Mehdi Farokhnia, Sophia Khom, Claire L. Pince, Sophie K. Elvig, Roman Vlkolinsky, Renata C. N. Marchette, George F. Koob, Marisa Roberto, Leandro F. Vendruscolo, Lorenzo Leggio

Summary: Growing evidence suggests the involvement of the GLP-1 system in addictive behaviors, and GLP-1 analogues like semaglutide may be a potential treatment for AUD. This study found that semaglutide dose-dependently reduced binge-like drinking in mice and also decreased alcohol intake in rats with binge-like and dependence-induced drinking. Additionally, semaglutide modulated GABA neurotransmission in the central amygdala and infralimbic cortex, indicating its potential as a novel pharmacotherapy for AUD.

JCI INSIGHT (2023)

Article Clinical Neurology

L-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

Ahmad Shamabadi, Farnaz Kafi, Melika Arab Bafrani, Hassan Asadigandomani, Fatemeh A. Basti, Shahin Akhondzadeh

Summary: This study found that adjunctive L-theanine, when combined with sertraline, showed better efficacy in treating major depressive disorder (MDD) compared to placebo. The L-theanine group demonstrated significant improvement in depression symptoms and a greater reduction in depression scores compared to the placebo group at weeks 2, 4, and 6. Furthermore, the L-theanine group had higher remission and response rates at week 6. These findings suggest that L-theanine is a safe and effective adjunctive therapy for MDD.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Article Psychiatry

Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study

Sara Momtazmanesh, Sahar Ansari, Zahra Izadi, Parnian Shobeiri, Venus Vatankhah, Arash Seifi, Fereshteh Ghiasvand, Mahboobeh Bahrami, Mohammdreza Salehi, Ahmad Ali Noorbala, Shahin Akhondzadeh

Summary: This study investigates the efficacy and safety of famotidine in improving cognitive impairment, depression, and anxiety symptoms post-COVID-19. The results show that patients in the famotidine group had significantly higher MMSE and MoCA scores, as well as reduced HAM-D and HAM-A scores, compared to the placebo group. The study suggests that famotidine is safe and effective in treating cognitive impairment, depression, and anxiety symptoms induced by COVID-19.

JOURNAL OF PSYCHOSOMATIC RESEARCH (2023)

Meeting Abstract Substance Abuse

CONVERGING EVIDENCE FROM RODENT AND HUMAN STUDIES ON THE ROLE OF SPIRONOLACTONE AS A POTENTIAL PHARMACOTHERAPY FOR ALCOHOL USE DISORDER

Mehdi Farokhnia, Christopher T. Rentsch, Vicky Chuong, M. Adrienne McGinn, Sophie K. Elvig, Eliza A. Douglass, Luis A. Gonzalez, Jenna E. Sanfilippo, Renata C. N. Marchette, Brendan J. Tunstall, David A. Fiellin, George F. Koob, Amy C. Justice, Lorenzo Leggio, Leandro F. Vendruscolo

ALCOHOL (2023)

Article Obstetrics & Gynecology

Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial

Sophia Esalatmanesh, Ladan Kashani, Maryam Khooshideh, Hossein Sanjari Moghaddam, Sahar Ansari, Shahin Akhondzadeh

Summary: The study aimed to assess the effects of adjunctive celecoxib with cognitive behavioral therapy (CBT), an anti-inflammatory agent, in the treatment of postpartum depression. The results showed that adjunctive celecoxib is effective in improving postpartum depressive symptoms.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2023)

Article Psychiatry

Relationship between self-stigma about alcohol dependence and severity of alcohol drinking and craving

Madeline E. Crozier, Mehdi Farokhnia, Susan Persky, Lorenzo Leggio, Brenda Curtis

Summary: Self-stigma is associated with the severity of alcohol use disorder and craving. Higher levels of self-stigma are related to more severe AUD, greater alcohol consumption, and more obsessive thoughts and compulsive behaviors related to alcohol.

BMJ MENTAL HEALTH (2023)

No Data Available